Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.

about

Molecular characteristics of colorectal cancer in a Middle Eastern population in a single institution

P2860

Q58803324-6689AB94-AA62-41E7-A9AA-8EB207EAEDA4

P2860

Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.

Item

http://www.wikidata.org/entity/Q39334444

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.

@en

Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.

@nl

type

Item

label

Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.

@en

Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.

@nl

prefLabel

Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.

@en

Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.

@nl

P1476

Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.

@en

P2093

Larissa V Furtado

http://www.w3.org/2001/XMLSchema#string

Wade S Samowitz

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations of two PMS homologues in hereditary nonpolyposis colon cancer

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

Comprehensive molecular characterization of human colon and rectal cancer

Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

P2888

s00428-017-2153-8

P31

scholarly article

P356

10.1007/S00428-017-2153-8

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28551725

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.

about

P2860

P2860

Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698

P921